What's interesting is Parkinson's seemed to be on the back burner and downplayed for quite awhile. No one knew if Renishaw's convection-enhanced delivery of MANF would make it past the brain barrier successfully to treat Parkinson's Disease. That's why there is research. That's why they say there is risk. That's why AMBS is not a one trick pony. There are a half dozen assets of billion plus potential. All you need is one and it doesn't happen overnight.

This is really great news that it worked and MANF for Parkinson's can move forward. This is even better news for those that suffer from the disease as potentially there's another path of potential success and hope for them. I know some investors don't care about that unless one day they wake up with the disease and their whole world changes overnight.

Didn't expect the market to react or understand as you have to be following the story for a few years. We already know the potential for MANF for ophthalmology and now the company has a delivery mechanism for Parkinson's. This is the reason why you see MANF for Parkinson's on the Therapeutics Pipeline .

The spring is being tightly wound. Analysts can see it. Just a matter of what is the trigger. Hang in there my friend. It's going to be quite a ride.